Abstract 611P
Background
The ESMO-MCBS provides a standardized assessment of the clinical benefit of a study treatment, considering factors such as overall survival and quality of life. We examined the profile of scores for trials of adjuvant therapy or potentially curative therapies presented at ASCO22 to assess the applicability of the MCBS.
Methods
Abstracts and prior or subsequent (until April 10, 2023) full publications of phase 3 trials on adjuvant therapy or curative treatment presented at ASCO22 were assessed using the MCBS v1.1 evaluation form 1. Scores were calculated based on overall survival, disease free survival or pathological complete response data and graded as A, B or C. Grades A and B indicate a substantial magnitude of clinical benefit. Two independent reviewers performed the grading; discrepancies were resolved through discussion and consensus with a third investigator.
Results
Thirty-five trials were evaluated, of which 11 could not be scored due to insufficient data or endpoint not gradable of the remaining 24 trials, 12 could not be graded due to statistically non-significant results. The remaining 12 trials were scored based on abstract alone (n= 6), or subsequent publication (n=6). A meaningful clinical benefit was seen in 11 of 12 trials (92%) with a score of A (n=9) or B (n=2), whereas 1 study had a score C.
Conclusions
Applying the current ESMO-MCBS to adjuvant and curative phase 3 trials presented at ASCO22 has significant limitations, due to the number of trials not able to be scored. This is a particular problem for studies with non-significant results. Adapting the score to allow grading of all trials may better assist clinicians and patients to assess the value of contemporary research.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
E. Segelov: Non-Financial Interests, Personal, Member: ESMO-MCBS Working Group. All other authors have declared no conflicts of interest.
Resources from the same session
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract